CavGene Therapeutics
East Lansing · Founded 2022
About CavGene Therapeutics
CavGene utilizes gene therapy to treat levodopa induced dyskinesia (LID) in patients with Parkinson’s Disease.
Company Facts
- Founded: 2022
- Legal name: CavGene Therapeutics, Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Funding stage: Seed
- Last round: Pre-Seed (Feb 2023)
- Website: cavgene.com
Canonical: https://fsome.com/organization/cavgene-therapeutics-8382670 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.